Details

Autor(en) / Beteiligte

• Anthwal, Divya
• Jamwal, Shaina
• Gupta, Rakesh Kumar
• Singhal, Ritu
• Verma, Ajoy Kumar
• Bhalla, Manpreet
• Myneedu, Vithal Prasad
• Sarin, Rohit
• Choudhary, Sangeeta
• Tyagi, Jaya Sivaswami
• Haldar, Sagarika

Titel

Direct Molecular Detection of Drug-Resistant Tuberculosis from Transported Bio-Safe Dried Sputum on Filter-Paper

Ist Teil von

• Current microbiology, 2022-04, Vol.79 (4), p.110-110, Article 110

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2022

Link zum Volltext

Quelle

SpringerLink

Beschreibungen/Notizen

• In 2019, amongst half a million new rifampicin-resistant tuberculosis (TB) cases, 78% were multi drug-resistant TB (MDR-TB). Access to rapid and Universal-Drug susceptibility testing (DST) to patients in remote areas is a major challenge to combat drug-resistant TB. To overcome this challenge, we had recently reported the development of ‘TB Concentration & Transport kit’ for bio-safe ambient temperature transport of dried sputum on filter-paper ( Trans -Filter). The present study was conducted to evaluate the utility of DNA extracted from sputum on Trans -Filter in a Multiplex PCR-based sequencing assay (Mol-DSTseq) for diagnosing drug-resistant TB. The developed Mol-DSTseq assays were standardized on Mycobacterium tuberculosis clinical isolates ( n  = 98) and further validated on DNA extracted from sputum on Trans -Filter ( n  = 100). Using phenotypic DST as gold standard, the Mol-DSTseq assay showed 100% (95% Confidence Interval [CI] 79.4–100%) and 73.3% (95% CI 54.1–87.7%) sensitivity for detecting rifampicin and isoniazid resistance with a specificity of 85.1% (95% CI 66.2–95.8%) and 100% (95% CI:82.3–100%), respectively. For fluoroquinolones and aminoglycosides, the Mol-DSTseq assay showed a sensitivity of 78.5% (95% CI 49.2–95.3%) and 66.6% (95% CI 9.4–99.1%) with a specificity of 88.2% (95% CI 72.5–96.7%) and 100% (95% CI 93.1–100%), respectively. The Mol-DSTseq assays exhibited a high concordance of ~ 83–96% ( κ value: 0.65–0.81) with phenotypic DST for all drugs. In conclusion, the ‘TB Concentration and Transport kit’ was compatible with Mol-DSTseq assays and has the potential to provide ‘Universal-DST’ to patients residing in distant areas in high burden countries, like India for early initiation of anti-tubercular treatment.